MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Open Access
- 15 April 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (5), 2257-2267
- https://doi.org/10.1172/jci67816
Abstract
Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyrosine kinase with oncogenic properties that is often overexpressed or activated in various malignancies. Using both protein immunohistochemistry and microarray analyses, we demonstrate that MERTK expression correlates with disease progression. MERTK expression was highest in metastatic melanomas, followed by primary melanomas, while the lowest expression was observed in nevi. Additionally, over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. Stimulation of melanoma cells with the MERTK ligand GAS6 resulted in the activation of several downstream signaling pathways including MAPK/ERK, PI3K/AKT, and JAK/STAT. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells. This work establishes MERTK as a therapeutic target in melanoma and provides a rationale for the continued development of MERTK-targeted therapies.Keywords
This publication has 38 references indexed in Scilit:
- Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancerOncogene, 2012
- Reviewing the somatic genetics of melanoma: from current to future analytical approachesPigment Cell & Melanoma Research, 2012
- Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphologyOncogene, 2011
- Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032Radiotherapy and Oncology, 2011
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- NCBI GEO: archive for functional genomics data sets--10 years onNucleic Acids Research, 2010
- A genomic screen identifies TYRO3 as a MITF regulator in melanomaProceedings of the National Academy of Sciences of the United States of America, 2009
- The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasisBMC Medical Genomics, 2008
- Prognostic Significance of Autoimmunity during Treatment of Melanoma with InterferonThe New England Journal of Medicine, 2006
- Phagocytosis and clearance of apoptotic cells is mediated by MERNature, 2001